Latest News
Beryllium starts development of MCL-1 platform
29 May 2015 - Beryllium, a scientific research services company, in collaboration with the Broad Institute of MIT and Harvard, has started development of an MCL-1 platform for structure-guided drug discovery, it was announced on Thursday.The organisations are developing a crystallographic platform for MCL-1 that uses a combination of fusion protein and sequence engineering. The new methods enable systematic screening against MCL-1, paving the way to structure based drug design.Dalia Cohen, Ph.D., CSO and Head of Research for Beryllium, said, 'This is an important development in the enablement of a fragment and structure-based drug design platform for MCL-1. With this platform, we are now uniquely suited to screen and explore structure activity relationships to optimize hits and leads in target development.'
Login
Username:

Password: